Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

被引：0
|
作者：
James Amamoo [1 ]
Riddhi Doshi [2 ]
Joshua Noone [1 ]
Lin Xie [1 ]
Cory Gamble [1 ]
Mico Guevarra [1 ]
Victoria Divino [2 ]
Justin Chen [2 ]
Aaron King [3 ]
机构：
[1] Novo Nordisk Inc.,
[2] IQVIA,undefined
[3] MedFirst Primary Care – Quarry,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
BMI; GLP-1 receptor agonist; HbA1c; Healthcare resource utilization; Real-world evidence; Semaglutide; SGLT2i; Type 2 diabetes; Weight;
D O I：
10.1007/s13300-025-01721-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1048
页数：15
相关论文
共 50 条
  • [41] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Torimoto, Keiichi
    Okada, Yosuke
    Koikawa, Kenji
    Tanaka, Yoshiya
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [42] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Keiichi Torimoto
    Yosuke Okada
    Kenji Koikawa
    Yoshiya Tanaka
    Diabetology & Metabolic Syndrome, 9
  • [43] Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
    Andrew McGovern
    Michael Feher
    Neil Munro
    Simon de Lusignan
    Diabetes Therapy, 2017, 8 : 365 - 376
  • [44] Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study
    Schmedt, Niklas
    Enders, Dirk
    Muller, Felix
    Walker, Jochen
    Garbe, Edeltraut
    Douros, Antonios
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 38 - 39
  • [45] Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
    McGovern, Andrew
    Feher, Michael
    Munro, Neil
    de Lusignan, Simon
    DIABETES THERAPY, 2017, 8 (02) : 365 - 376
  • [46] Type 2 Diabetes Mellitus and the Gut Microbiota: Charting New Territory for Sodium-Glucose Co-Transporter 2 Inhibitors
    Stepanova, Natalia
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2024, 8 (01): : 1 - 8
  • [47] Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors
    Spela Zerovnik
    Mitja Kos
    Igor Locatelli
    Acta Diabetologica, 2022, 59 : 233 - 241
  • [48] Sodium-glucose co-transporter 2 inhibitors and the risk of early breast cancer among women with type 2 diabetes
    Suissa, Melanie
    Yin, Hui
    Yu, Oriana
    Wong, Stephanie
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 476 - 476
  • [49] Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy
    Takenaka, Tsuneo
    Kishimoto, Miyako
    Ohta, Mari
    Tomonaga, Osamu
    Suzuki, Hiromichi
    DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (03): : 258 - 261
  • [50] Predictors of Glycemic and Weight Response to Exenatide Once-Weekly in Patients with Type 2 Diabetes in a Real-World Setting
    Gorgojo-Martinez, Juan J.
    Brito-Sanfiel, Miguel A.
    Gargallo-Fernandez, Manuel A.
    Lisbona-Catalan, Arturo
    DIABETES, 2017, 66 : A297 - A297
12345